VYVGART® (efgartigimod alfa) is indicated for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
Please consult the VYVGART® Product Monograph or click here for important information relating to:
- Contraindications in patients with hypersensitivity to VYVGART® or any ingredient in the formulation or component of the container.
- Other relevant warnings and precautions regarding infections, including upper respiratory tract infections and urinary tract infections, vaccination, fertility, hypersensitivity and infusion-related reactions, pregnancy, and breast-feeding.
- Conditions of clinical use, adverse reactions, drug interactions, and dosing information.
The Product Monograph is also available by calling argenx Medical Information at 1-800-731-8917.
